Details

Autor(en) / Beteiligte

• Whitney, Cynthia G
• Farley, Monica M
• Hadler, James
• Harrison, Lee H
• Bennett, Nancy M
• Lynfield, Ruth
• Reingold, Arthur
• Cieslak, Paul R
• Pilishvili, Tamara
• Jackson, Delois
• Facklam, Richard R
• Jorgensen, James H
• Schuchat, Anne

Titel

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

Ist Teil von

• The New England journal of medicine, 2003-05, Vol.348 (18), p.1737-1746

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2003

Quelle

MEDLINE

Beschreibungen/Notizen

• In 2000, a protein–polysaccharide pneumococcal conjugate vaccine was recommended for use in infants and young children. Surveillance data show that from 1998 to 2001 the rate of invasive disease declined by 69 percent among children less than two years of age. There were also smaller but significant reductions in pneumococcal disease in adults. Pneumococcal sepsis and meningitis are less frequent in infants and young children. In early 2000, a 7-valent protein–polysaccharide pneumococcal conjugate vaccine (Prevnar, Wyeth Lederle Vaccines) was licensed for use in infants and young children in the United States. This was the first vaccine that promised efficacy against pneumococcal disease for this high-risk group. In the second half of 2000, recommendations for routine use of the vaccine in all infants and children under two years of age and in high-risk children two through four years of age were published, 1 , 2 and distribution of the vaccine through public programs began. By August 2001, a shortage was reported. 3 Controlled clinical trials have shown that the . . .